Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 May 22;16(1):69.
doi: 10.1186/s12933-017-0551-5.

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

Arwa Younis  1   2 , Dana Eskenazi  3 , Ronen Goldkorn  4   3 , Jonathan Leor  4   3 , Nili Naftali-Shani  4   3 , Enrique Z Fisman  3   5 , Alexander Tenenbaum  4   3   5 , Ilan Goldenberg  4   3   6 , Robert Klempfner  4   3
Affiliations
Randomized Controlled Trial

The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study

Arwa Younis et al. Cardiovasc Diabetol. .

Abstract

Background: Patients with type 2 diabetes present with an accelerated atherosclerotic process. Animal evidence indicates that dipeptidyl peptidase-4 inhibitors (gliptins) have anti-inflammatory and anti-atherosclerotic effects, yet clinical data are scarcely available.

Design and methods: A prospective, randomized, open-label study was performed in 60 patients with coronary artery disease (CAD) and type 2 diabetes, who participated in a cardiac rehabilitation program. After a washout period of 3 weeks, patients were randomized in a 2:1 ratio to receive combined vildagliptin/metformin therapy (intervention group: n = 40) vs. metformin alone (control group: n = 20) for a total of 12 weeks. Blinded assessment of interleukin-1ß (IL-1ß, the primary endpoint), hemoglobin A1c (HbA1c), and high sensitivity C reactive protein (hsCRP), were performed at baseline and after 12 weeks.

Results: Mean age of study patients was 67 ± 9 years, 75% were males, and baseline HbA1c and inflammatory markers levels were similar between the two groups. At 12 weeks of follow up, levels of IL-1ß, hsCRP, and HbA1c were significantly lower in the intervention group as compared with the control group. There was a continuous elevation of IL-1ß among the control group, which was not observed in the intervention group (49 vs. 4%, respectively; p < 0.001). The hsCRP was lowered by 60% in the vildagliptin/metformin group vs. 23% in the metformin group (p < 0.01). Moreover, a significant relative reduction of the HbA1c was seen in the intervention group (7% reduction, p < 0.03).

Conclusion: The addition of vildagliptin to metformin treatment in patients with type 2 diabetes and CAD led to a significant suppression of the IL-1ß elevation during follow up. A significant relative reduction of hsCRP and HbA1c in the intervention group was also observed. Trial registration NCT01604213.

Keywords: Dipeptidyl peptidase-4 inhibitors; Gliptins; Interleukin 1 beta; Metformin; Vildagliptin.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study flow diagram
Fig. 2
Fig. 2
a Levels of IL-1ß at baseline and after 12 weeks of treatment; b Percent change of IL-1ß {Δ% = [(value after treatment−baseline value)/baseline value × 100]}
Fig. 3
Fig. 3
a hsCRP values at baseline and follow up b hsCRP percentage change after 12 weeks of treatment
Fig. 4
Fig. 4
a HbA1c % values at baseline and follow-up b HbA1c percentage change after 12 weeks of treatment
See this image and copyright information in PMC

References

    1. Kochanek KD, Murphy SL, Xu J, Tejada-Vera B. Deaths: final data for 2014. Natl Vital Stat Rep Cent Dis Control Prev Natl Center Health Stat Natl Vital Stat Syst. 2016;65(4):1–122. - PubMed
    1. Park J, Peters PA. Mortality from diabetes mellitus, 2004 to 2008: a multiple-cause-of-death analysis. Health Rep. 2014;25(3):12–16. - PubMed
    1. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Exp Rev Endocrinol Metab. 2010;5(1):19–28. doi: 10.1586/eem.09.44. - DOI - PMC - PubMed
    1. Faeh D, William J, Yerly P, Paccaud F, Bovet P. Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity. Cardiovasc Diabetol. 2007;6:32. doi: 10.1186/1475-2840-6-32. - DOI - PMC - PubMed
    1. Colwell JA, Lopes-Virella M, Halushka PV. Pathogenesis of atherosclerosis in diabetes mellitus. Diabetes Care. 1981;4(1):121–133. doi: 10.2337/diacare.4.1.121. - DOI - PubMed

Publication types

MeSH terms

Associated data